CERO THERAPEUTICS HOLDINGS, INC.

Communiqués CERo Therapeutics Holdings, Inc.

Actions

CERO

US71902K1051

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 06/06/2024			Varia. 5j.	Varia. 1 janv.
0,7559 ^USD	-16,47%		-22,28%	-93,13%

06/06	CERo Therapeutics, Inc. achève avec succès les études toxicologiques permettant l'obtention d'une IND pour son composé principal CER-1236	CI
17/05	CERo Therapeutics Holdings, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236	06/06	GL
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders	15/05	GL
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes	30/04	AQ
PHOX BIOT26 : CERo Therapeutics Investor Presentation	25/04	PU
CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients	07/03	BU
Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination	14/02	BU
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics	05/06/23	BU
PHOENIX BIOTECH ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	07/04/23	AQ
PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	24/03/23	AQ
PHOENIX BIOTECH ACQUISITION CORP. : Other Events (form 8-K)	27/01/23	AQ
PHOENIX BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	20/12/22	AQ
PHOENIX BIOTECH ACQUISITION CORP. : Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	07/12/22	AQ
PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	10/11/22	AQ
PHOENIX BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	31/10/22	AQ
PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	11/08/22	AQ
PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	13/05/22	AQ
PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	24/03/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Bourse
Actions
Action CERO
Actualités CERo Therapeutics Holdings, Inc.
Communiqués

Tous les transcripts sur plus de 9000 sociétés, le jour de leur publication !

Débloquez-les Maintenant !

fermer